drugset / Trial / NCT00541385

Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients

NCT00541385

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this Phase III clinical study is to demonstrate the efficacy of the fixed combination of pyronaridine artesunate (PA) granule formulation (60:20 mg; pediatric PYRAMAX®) by showing a PCR-corrected adequate clinical and parasitological cure rate (ACPR) of more than 90%. Secondary objectives of this clinical study are to compare the efficacy (non-inferiority) and safety of the PA granule formulation compared to Coartem® (ie, the combination of artemether/lumefantrine \[AL\]) crushed tablets in a paediatric population and to assess the safety of the PA granule formulation.

Timeline

Start
2007-10
Primary completion
2008-09
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artemether Small molecule 20 mg Oral
Comparator Artemether Small molecule 40 mg Oral
Subject Artesunate Small molecule 2.3 mg/kg Oral
Subject Artesunate Small molecule 4.4 mg/kg Oral
Subject Pyronaridine Unknown 7 mg/kg Oral
Subject Pyronaridine Unknown 13.3 mg/kg Oral
Comparator lumefantrine Small molecule 120 mg Oral
Comparator lumefantrine Small molecule 240 mg Oral

Indications